Coverage and Payment for Prescription Drugs Under Medicare Part B: A Complex Patchwork by Cassidy, Amanda
OVERVIEW — As part of the diverse discussions around health care 
reform, many have looked to refining Medicare payment systems 
as a way to give health care practitioners and providers greater 
incentives to deliver care more efficiently, and thus slow health care 
spending growth. Understanding how Medicare currently pays for 
Part B services, including drugs covered under Part B, is essential to 
understanding the potential impact of these types of reforms. Most 
items and services covered under Part B, including most Part B 
drugs, are paid individually, which means practitioners and provid-
ers generally receive more payments for providing more services. 
Some reform proposals would expand the use of bundled payments 
under Medicare to pay for items and services as a group, rather 
than separately, to curb incentives to provide unnecessary care. If 
such reforms were to include Part B drugs, it would be a significant 
change from current payment policies. A close look at coverage and 
payment for Part B drugs reveals complex policies and interactions 
with Part D drug coverage.
B a c k g r o u n d 
P a P e r   No. 70
August 31, 2009
coverage and Payment for Prescription 
drugs under Medicare Part B:
a complex Patchwork
aManda cassidy, Consultant
August 31, 2009 NAtioNAl HeAltH Policy Forum 
2
National Health Policy Forum







Judith miller Jones 
Director




the National Health Policy Forum is a 
nonpartisan research and public policy 
organization at the george Washington 
university. All of its publications since 1998 
are available online at www.nhpf.org.
contents
meDicAre Drug coVerAge...............................................................3
 Basics of Part B Drug coverage ...................................................3
 Figure 1: Part B Drug spending in 2007 by setting ......................4
 table 1: examples of Bills expanding  
 coverage of Part B Drugs............................................................5
meDicAre PAymeNt Policy ...............................................................8
 Payment Basics for Part B Drugs ..................................................8
 table 2: Basis for Part B Drug Payments by setting ......................9
 Bundled Versus separate Payment ..............................................13
 Payments in Different settings ....................................................14
 table 3: Payment may Vary Depending on site of service ...........14
 Beneficiary out-of-Pocket costs ..................................................15
AssessiNg PArt B Drug PAymeNt Policy ........................................16
coNclusioN .......................................................................................17
eNDNotes ...........................................................................................17
APPeNDiX A: Drug Pricing Alphabet soup .............................................21
APPeNDiX B: Weighing the options: is Part B or Part D  
Better for the Beneficiary? .....................................................................22
www.nhpf.org
3
B a c k g r o u n d 
P a P e r   No. 70
Medicare Part B covers certain outpatient drugs used in specific set-
tings or to treat specific conditions, and its coverage has expanded 
incrementally since Medicare was created in 1965. Multiple pay-
ment systems and fee schedules are used to establish the payments 
for Part B drugs. Those payment systems and fee schedules may 
produce different payment amounts for practitioners and provid-
ers and different cost-sharing for beneficiaries for the same drug, 
depending on the setting in which it is administered. As a result of 
various coverage requirements and payment methodologies, prac-
titioners, providers, beneficiaries, Medicare claims processing con-
tractors, and prescription drug plans must determine which part 
of Medicare should be paying for a drug under particular circum-
stances, which, in turn, will determine how much Medicare and the 
beneficiary will pay.
This paper explores (i) coverage: the types of drugs and circum-
stances under which they may be covered by Part B and (ii) payment: 
how Part B payment and beneficiary cost-sharing is determined in 
different treatment settings.
Medicare drug coVerage
All of the different parts of Medicare—Parts A, B, C and D—pay for 
prescription drugs. Parts A and B of Medicare pay for inpatient and 
outpatient medical services, respectively. Together they are referred 
to as traditional, or fee-for-service (FFS), Medicare. Part C, the Medi-
care managed care program, pays private plans a monthly rate to 
cover the same services covered under traditional Medicare.1 Part 
D, the Medicare prescription drug benefit, pays private plans to ad-
minister most outpatient drug coverage, but under certain circum-
stances some outpatient drugs may be covered under Part B.2 The 
Centers for Medicare & Medicaid Services (CMS) has responsibility 
for the four parts of Medicare and contracts with claims processing 
contractors and private plans to administer the program.
Basic s of Par t B drug coverage
Part B drugs are primarily administered in physician offices, hospital 
outpatient departments, or end stage renal disease (ESRD) facilities 
or with the use of durable medical equipment (DME), such as an in-
fusion pump. In 2007, the Medicare Payment Advisory Commission 
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(MedPAC) estimated that payment for Part B drugs 
in these settings totaled $16.8 billion.3 To put this 
number in perspective, Part B drugs accounted for 
roughly 10 percent of all spending on Part B services 
in 2007 and one-third of the amount spent on Part D 
drugs in that year.4 Figure 1 shows a breakdown of 
spending on Part B drugs in 2007 by setting.
While Part B covers more than 675 individual 
drugs, spending is concentrated on a small num-
ber of drugs: 10 account for almost half of Part B 
drug spending.5 Most of those high-cost drugs are 
for treatment of cancer or the side effects of chemo-
therapy such as anemia. 
Part B drug coverage grew in a piecemeal fashion over 
many years through many different pieces of legisla-
tion. Table 1 (next page) shows examples of specific 
coverage added by some of the major Medicare bills 
passed over the last two decades. The cost of expanded coverage was 
often an important consideration, so the statutory language can be 
extremely specific about when and for whom a drug is covered. 
To be covered under Part B, a drug must fulfill two requirements. 
First, it must be included in one of the groups of items and services 
listed in the statute that are covered by Medicare.6 Second, individ-
ual items that fall within a covered group must also be considered 
“reasonable and necessary” under the Medicare law. 
Most Part B–covered drugs are considered part of a larger group of 
services such as physician services, hospital outpatient services, or 
ESRD services.7 Generally, Part B covers five types of drugs:
Physician-administered drugs• 
DME-administered drugs• 
Certain oral drugs • 
Vaccines• 
Other drugs in certain circumstances• 
Physician-administered drugs — Drugs that are administered by a physi-
cian or professional staff in a clinical setting, such as a hospital out-
patient department or physician’s office, typically through infusion 
Physician Office
(includes DME and 






Source:  Medicare Payment Advisory Commission (MedPAC), A 
Data Book: Healthcare Spending and the Medicare Program, June 
2009; available at www.medpac.gov/documents /Jun09DataBook 
entirereport.pdf.
FigurE 1 Part B Drug Spending in 2007   
 by Setting
 
  Total spending — $16.8 billion 
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or injection, are covered under Part B. Because the act of administer-
ing the drug is covered as a physician or hospital outpatient service, 
the drug being administered is also covered. Such drugs are often 
referred to as “incident to” drugs because they fall into the group of 
covered services that are “incident to a physician service.” 
The law requires that “incident to” drugs be classified as “not usual-
ly self-administered,” which means that the drug cannot be admin-
istered by the patient or caregiver more than 50 percent of the time. 
Drugs that are administered intravenously or intramuscularly are 
presumed to be not self-administered, whereas oral drugs are pre-
sumed to be self-administered. Drugs that are administered through 
injection into the layer of fatty tissue just below the skin (called a 
subcutaneous injection) may or may not be self-administered. Sub-
cutaneous drugs used to treat chronic conditions are more likely to 
be considered self-administered than those to treat acute conditions.8 
TaBlE 1




act (oBra) of 1993
covered off-label uses of anti-cancer 
drugs that are cited in certain compendia 
or supported by clinical evidence in peer-
reviewed medical literature
Balanced Budget 
act (BBa) of 1997
covered oral anti-nausea drugs for use 








act (BiPa) of 2000
eliminated time limitation on coverage 




covered intravenous immunoglobulin 
(iVig) for treatment of primary immune 
deficiency in the home
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CMS has instructed its claims processing contractors to determine 
whether or not a drug is usually self-administered for their jurisdic-
tions.9 Each contractor publishes its list of usually self-administered 
drugs, and those drugs are not covered under Part B in the contrac-
tor’s jurisdiction, even if the drug is administered by a physician. 
In 2008, the number of drugs on the usually self-administered lists 
ranged from 14 for one contractor to 41 for others.10 
Dme-administered drugs — CMS interprets the Medicare DME benefit 
to include certain drugs because they are essential to the function-
ing of items that are covered under Part B as DME. For example, a 
nebulizer is a device that administers aerosolized medicine to treat 
respiratory disease; it stands repeated use and is covered under the 
DME benefit. Inhalation drugs are covered under Part B when used 
with a nebulizer, because the nebulizer could not fulfill its medical 
purpose without the drug. Inhalation drugs provided through other 
mechanisms that are not considered DME, such as multi-dose inhal-
ers, are not covered under Part B. In addition to inhalation drugs, in-
fusion drugs may be covered under the DME benefit if administered 
through an infusion pump that is covered under the benefit. 
Limitations that apply to other DME items also apply to drugs cov-
ered under the DME benefit. For example, as defined by statute, the 
DME benefit does not apply to beneficiaries in an inpatient setting 
such as a skilled nursing facility (SNF) or hospital. If administered 
in an inpatient facility, a drug covered under the DME benefit in a 
patient’s home would not be covered under Part B, even if Medicare 
is not paying for the inpatient stay.11
oral drugs — Most oral drugs are not administered by a physician 
and generally are considered self-administered. However, the law 
does allow for Part B coverage of certain oral drugs under specific 
circumstances:
Immunosuppressive drugs for beneficiaries who have received a • 
Medicare-covered organ transplant 
Oral anti-cancer drugs that have the same active ingredients and • 
are used for the same indications as forms of the drug that are cov-
ered incident to a physician service 
Oral anti-nausea drugs if used as part of an anti-cancer regimen • 
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Oral drugs are typically obtained from community or mail order 
pharmacies, whose interaction with Part B is limited. This may intro-
duce additional administrative complexities for these pharmacies. 
Prescription drug plans must sort out whether these drugs are cov-
ered under Part B or Part D. (See text box below.)
Vaccines — The law requires Part B coverage of preventive vaccines 
for influenza, pneumococcus, and hepatitis B. Part B does not cover 
most other preventive vaccines, but they may be covered under Part 
D. However, Part B will cover vaccines when they are used for the 
treatment of illness or injury (for example, a tetanus shot after step-
ping on a nail). 
other drugs — The Medicare statute requires coverage of a few other 
drugs under very specific circumstances. For example, Part B cov-
ers parenteral nutrition (feeding a person intravenously), but only for 
patients who are receiving such therapy because of a non-function-
ing digestive tract. Intravenous immunoglobulin (IVIG) provided in 
the home is covered under Part B for patients with primary immune 
Part B vs. Part D
The same drug may be covered under different parts of the Medicare program, depending on the circum-
stances under which it is administered. By law, drugs covered by Part A or B of Medicare are not Part D 
drugs. The complexity and variation in Part B coverage can make it challenging to determine whether a drug 
is covered under Part B or Part D. Medicare fee-for-service claims processing contractors and Part D plans 
must sort through these intricacies to determine which part of Medicare should be paying for a particular 
drug. Prescription drug plans must be familiar with both general Part B coverage and with the specific 
drugs that are covered under Part B by contractors in their plan coverage area. Drugs that are considered 
usually self-administered by one contractor in one area—and therefore could be Part D drugs—may be 
covered under Part B by other contractors in other areas. Mode of administration suggests whether Part B 
or Part D is probably responsible for coverage, but is not a definitive guideline. The key factor is how the 
drug is prescribed and dispensed in the specific circumstance for a particular patient. A drug typically 
covered by Part B may be a Part D drug if it is filled at a community or mail order pharmacy. 
This complexity precludes prescription drug plans from basing coverage determinations solely on the item 
being prescribed, although this may be the only information initially provided to them. The structure of 
Part D, which puts plans at risk to manage beneficiary drug costs, creates incentives for plans to ensure 
that they do not pay for drugs that should be paid for under Part B. 
The Part B versus Part D determination can affect how much is paid for the drug in question and how 
much cost sharing the beneficiary must pay. See the "Beneficiary Out-of-Pocket Costs" (p. 15) and Appendix 
B (p. 22) for more information. 
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deficiency disease. Blood clotting factor for hemophilia patients is 
covered even if it is self-administered. Also covered under Part B are 
blood products, antigens, therapeutic radiopharmaceuticals, and di-
agnostic radiopharmaceuticals and contrast media for imaging.
Medicare PayMenT PoLicy
Setting an appropriate payment rate for Part B drugs has been chal-
lenging for policymakers. Paying too much or too little can distort 
clinical decision making about the use of certain drugs, which can 
have repercussions on the health of Medicare beneficiaries and the 
financial well-being of the program. 
Paying for drugs at rates that are significantly greater than the cost 
of acquiring the drugs creates incentives for physicians to provide 
more drugs.12 Paying too little for drugs also has adverse conse-
quences. Continued underpayment for a drug could affect benefi-
ciary access if providers are unable or unwilling to offer that drug 
because the payment does not cover their costs. The effect of un-
derpayment may not be that a drug becomes unavailable but rather 
that it is administered in a different setting. For example, rather than 
administering the drug in the office where the physician practice is 
responsible for purchasing the drug, the physician could refer the 
beneficiary to the hospital to receive the drug. Under this scenario, 
the hospital would be responsible for purchasing the drug. Chang-
ing where the drug is obtained could inconvenience the beneficiary, 
and it could change the Medicare payment for the drug and its ad-
ministration. Alternatively, the physician may be willing to admin-
ister the drug in the office but not provide it, recommending that 
the patient obtain the drug from a community pharmacy and bring 
it to the office to be administered. This practice, called “brown bag-
ging,” raises concerns for some about the appropriate handling of 
the drug between the time it is dispensed by the pharmacy and 
administered by the doctor.13 
Payment Basic s for Par t B drugs
In understanding Medicare payment policy, it is important to re-
member that Medicare pays physicians, hospitals, and suppliers who 
have purchased drugs from manufacturers, wholesalers, or group 
purchasers. The Medicare program does not pay drug manufacturers 
www.nhpf.org
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directly for their products. The rates paid to practitioners and provid-
ers are set prospectively, based on market prices for the drugs. 
Because of the size of the Medicare program, the appropriate price 
in a market without Medicare as a purchaser may be very different 
from the price determined by a market that includes Medicare. With 
45 million, primarily aged, beneficiaries, the Medicare program has 
a substantial effect on drug sales volume and market price. Medicare 
approximates what an appropriate price should be through different 
approaches in different settings. These approaches include the aver-
age sales price (ASP), the average wholesale price (AWP), and the 
acquisition cost of the drug.
Medicare law specifies the basis of payment in different clinical set-
tings and, in most cases, also specifies the percentage of the amount 
that Medicare will pay. Payment for drugs administered in physi-
cian offices and ESRD facilities and inhalation drugs administered 
through DME is based on the ASP. Since the ASP reflects the average 
sales price, some sales occurred at or below that price and others oc-
curred above that price. In most instances, the payment rate required 
by law is greater than the ASP, allowing most providers to be able 
to obtain the drug without losing money on the transaction.14 Pay-
ment for infusion drugs administered through DME and the three 
preventive vaccines covered by Part B when provided in a physician 
office is based on the AWP. Payment for drugs 
administered in a hospital outpatient depart-
ment or an ambulatory surgical center is based 
on the average hospital acquisition cost, plus an 
amount for pharmacy overhead and handling 
costs. Table 2 shows the payment percentages 
for each setting. The different approaches to 
calculating prices under Part B are described 
below, and Appendix A provides a table sum-
marizing the terms.
Average wholesale price — Prior to 2005, payment 
for most Part B drugs was based on the AWP as 
listed in certain data sources such as Red Book. 
Often referred to as a “sticker price” that does 
not incorporate common discounts and rebates, 
AWP is a misnomer because it is neither an aver-
age price nor the price paid by wholesalers. Sev-
eral organizations, including the Government 
TaBlE 2
Basis for Part B Drug Payments by Setting
SETTiNg PayMENT BaSiS
Physician office 106% of ASP
ESrD Facility 106% of ASP
DME
inhalation Drugs 106% of ASP
infusion Drugs 95% of AWP*
Hospital outpatient 
Department / ambulatory 
Surgical Center 
Average hospital acquisition 
cost for the drug**
Preventive vaccines 95% of AWP
oral drugs provided by 
a pharmacy supplier
106% of ASP
 * As calculated October 1, 2003.
 ** In 2009, hospital outpatient department and ambulatory surgical center 
payment rates based on hospital acquisition costs are 104% of ASP.
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Accountability Office and the Office of the Inspector General (OIG) 
at the U.S. Department of Health and Human Services, studied the 
relationship between AWP and practitioner and supplier acquisi-
tion costs and found that practitioners and suppliers could obtain 
the drugs for considerably less than Medicare’s AWP-based payment 
rate.15 The Medicare Modernization Act of 2003 (MMA) subsequently 
shifted the basis for Medicare payment for most Part B drugs pro-
vided in the physician’s office from AWP to the average of the actual 
prices paid by all purchasers in the United States (the average sales 
price) for the drug beginning January 1, 2005. 
Following enactment of the MMA, the only payment for Part B drugs 
still based on AWP are drugs provided through infusion pumps un-
der the DME benefit, certain blood products, and the three Part B pre-
ventive vaccines when provided in settings other than a hospital out-
patient department.16 The payment rates for the vaccines and blood 
products are updated to reflect current AWPs. For DME infusion 
drugs, payment is based on the AWP in effect on October 1, 2003.
Average sales price — CMS calculates the ASP using data submitted 
by manufacturers on the sales prices of their drugs. Excluded from 
the ASP calculation are sales to certain government programs and 
safety net hospitals, as well as sales under state pharmaceutical as-
sistance programs and Part D.17 ASP is not to be confused with the 
average manufacturer’s price (AMP) used in the Medicaid drug re-
bate program.18 AMP is a similar calculation (see text box).
aSP vs. aMP
Medicare’s ASP and Medicaid’s AMP are both measures of average sales but they differ in several 
important ways. The universe of drug sales included in the AMP calculation is more limited, 
including only sales to the “retail class of trade”; in other words, pharmacies available to the 
general public. ASP includes sales for all classes of trade except those under certain government 
programs. Specific exclusions for government programs do not apply under AMP, so a sale to 
the retail class of trade may be excluded from ASP and included in the AMP calculation.  
Most discounts and rebates are included in the calculations of both ASP and AMP. The excep-
tion is customary "prompt pay" discounts, which are included in ASP but excluded from AMP. 
In general, AMP is greater than ASP. 
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Unlike AWP, ASP includes the various discounts and rebates offered 
by manufacturers that reduce the price paid for their drugs. The ar-
rangements between manufacturers and purchasers are varied and 
complex and can include discounts for prompt payment as well as 
those tied to the quantity or combination of drugs purchased. CMS 
has revised its regulations multiple times to attempt to fully account 
for the diverse arrangements used in the marketplace. However, 
questions remain about how well ASP captures the discounts and 
rebates that apply to the price paid by providers. Some discounts are 
difficult to assign to specific drugs for particular periods because 
they are based on total purchases for the year or tied to the com-
bination of drugs purchased. ASP might overstate the actual price 
for the drugs subject to these price concessions if they are not ap-
propriately attributed to the drugs involved. ASP might understate 
the price paid by providers if it reflects discounts to wholesalers that 
are not passed on to providers or if it does not fully reflect additional 
fees charged by wholesalers.19
Manufacturers provide product-specific sales data and CMS calcu-
lates the ASP, taking into consideration other products assigned to the 
same payment code. In some cases, only one drug is assigned to a pay-
ment code. In other instances, multiple drugs may be assigned to the 
same code, such as a brand name drug and its generic alternative.20
Manufacturers must submit the ASP data for their products within 
30 days of the end of each calendar quarter. CMS reviews the data 
and then calculates and releases the payment-level ASP data to its 
contractors and the public. Because of the time necessary to gath-
er, submit, and process ASP data, there is a six-month lag between 
when the sales occur and when the price of those sales will affect the 
Medicare payment rates. 
The MMA required the OIG to compare the ASP with two other 
methods for calculating price: AMP under Medicaid, and the price 
a prudent purchaser would pay for the drug (the widely available 
market price, or WAMP). The statute requires that CMS adjust pay-
ments for drugs that exceed AMP or WAMP by a certain threshold 
(to date the threshold has been 5 percent). Most recently, the OIG 
found that 5 percent of the drugs studied exceeded the threshold for 
the third quarter of 2008, and 80 percent of those drugs had exceed-
ed the threshold in previous quarters.21 Because of concerns about 
the lag between the time period involved in the study and when the 
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ASP study findings become available, CMS has not made any adjust-
ments to the payment rates based on the OIG findings.
Acquisition cost — In addition to AWP and ASP, Medicare may deter-
mine payment for a drug based on its acquisition cost, or the amount 
a Medicare provider actually pays for the drug in combination with 
the overhead costs to prepare the drug for administration. Because 
providers do not report their actual costs to Medicare, CMS must 
estimate those costs. 
For drugs provided in hospital outpatient departments, CMS uses 
the information providers submit on claims to estimate the com-
bined acquisition cost of drugs plus allocated pharmacy overhead. 
When a provider bills Medicare for treating a patient, it submits a 
claim that includes dollar values called charges for the services pro-
vided. The charge data are used to estimate the cost of providing the 
service. Because of the time necessary to receive and process claims 
and then for CMS to analyze information on those claims, the claims 
data used to set payment rates for a given year are typically two 
years old (that is, the data used to update the 2009 prospective pay-
ment systems are from 2007). The data are adjusted to approximate 
the later year costs. 
The payment for certain drugs is packaged into payment for asso-
ciated procedures. For others, the payment is made separately. For 
those drugs that are separately paid, the payment is based on the 
overall relationship between the costs of average acquisition and 
pharmacy overhead for hospital outpatient drugs (derived from the 
claims data) and the ASPs for those drugs. Separately payable drugs 
under the Outpatient Prospective Payment System (OPPS) were paid 
at ASP + 5 percent in 2008 and ASP + 4 percent in 2009.22 
There have been attempts to obtain acquisition data through pro-
vider surveys. Most recently, GAO conducted a survey of drug ac-
quisition costs for hospital outpatient departments in 2004 that was 
considered in setting OPPS payment rates.23 Providers maintain 
their acquisition data in a myriad of ways, making it difficult for the 
providers to gather the data and present it in a standardized form. 
Furthermore, a sufficient number of providers must participate in 
the survey in order to make its findings representative of providers 
who are not included. These complications make provider surveys 
costly and time-consuming, both to participate in and to administer. 
Once completed, the survey results present a snapshot of acquisition 
www.nhpf.org
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costs at a particular point in time that can be difficult to accurately 
update for later periods.24
Bundled Versus separate Payment
In some instances, Medicare pays for an item or service in combi-
nation or bundled with payment for other associated services. For 
example, Medicare pays for most inpatient hospital care by provid-
ing a prospectively determined lump sum payment for all items and 
services furnished during a hospital stay. Providing more services 
during a hospital stay generally will not increase Medicare payment. 
In contrast, most items and services under Part B are paid separately. 
Furnishing more items and services will increase Medicare payment. 
Most, but not all, Part B drugs currently receive separate payment.
The setting in which a drug is administered affects whether it is paid 
separately. Drugs provided in a physician office are paid separately. 
In other settings such as hospital outpatient departments and ESRD 
facilities, payment for some items and services is provided together, 
including some drugs. In those settings, newer or more expensive 
drugs often receive separate, individual payment. In ESRD facilities, 
drugs that were not included in the base payment unit (called the 
composite rate) when it was developed in the early 1980s, are paid 
separately. The ESRD payment system is being revised to expand 
the base bundle of services. By law, the expanded bundle, which is 
expected to be implemented January 1, 2011, will include drugs that 
are now separately payable. 
The OPPS uses a dollar threshold cost per day to determine whether 
a drug is paid separately. If the per-day costs for a drug are less than 
or equal to the annual drug packaging threshold, payment for the 
drug is included in payment for the services with which it is used. 
If the drug’s costs are greater than the threshold, then hospitals may 
receive separate payment for the drug. The threshold is updated an-
nually and is set at $60 for 2009.
Some have suggested that expanding the use of bundling could 
help address increasing spending on Part B drugs.25 Under current 
law, CMS could potentially expand bundling under certain pay-
ment systems such as the OPPS, or could experiment under a dem-
onstration project with bundling payments for all services related 
to a certain disease such as cancer.26 However, Congress would 
August 31, 2009 NAtioNAl HeAltH Policy Forum 
14
need to change the Medicare statute to incorporate bundled pay-
ments for drugs on a broader scale.
Payments in dif ferent set tings
Because payment rates and bundling policies differ, payment for the 
same drug can vary considerably from setting to setting. The most sig-
nificant contrast is between the physician office and the hospital out-
patient department, since most Part B–covered drugs can be provided 
in either setting. Drugs provided in physician offices are, by law, paid 
at ASP + 6 percent. Separately payable drugs under the OPPS were 
paid at ASP + 5 percent in 2008 and ASP + 4 percent in 2009.
The disparate payment rates and policies are evident for anti-cancer 
drugs. Such drugs may be provided in a physician office, hospital 
outpatient department, or, for certain drugs, through an infusion 
pump in a beneficiary’s home. Table 3 shows the first quarter 2009 
payment rate in these different settings for four cancer drugs. OPPS 
payment rates for drugs are consistently lower than physician office 
rates. DME rates may be considerably above or slightly below pay-
ment rates in other settings. Payment for some DME drugs is more 
than nine times the amount paid in other settings. Whereas the ASPs 
are updated quarterly, the payment rates for DME-provided drugs 
are frozen at the October 1, 2003, AWP.27 
TaBlE 3    Payment May vary Depending 
 on Site of Service












Bleomycin sulfate Blenoxane J9040 $ 31.83 Packaged (not paid separately)
$ 289.37
Doxorubicin HCl liposome Doxil J9001 $ 441.25 $ 432.93 $ 393.48
Cladribine leustatin J9065 $ 29.25 $ 28.70 $ 61.72
Trastuzumab Herceptin J9355 $ 61.64 $ 60.48 $ 58.13
Source: CMS, "January 2009 ASP Pricing File," available at www.cms.hhs.gov/mcrPartBDrugAvgsalesPrice/01a1_2009aspfiles.
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Beneficiary out-of-Pocket costs
In most cases, beneficiaries in traditional Medicare pay a portion of 
the cost of their health services. For Part B drugs, once a beneficiary 
meets the annual deductible, the Medicare program pays 80 percent 
of the total payment amount and the beneficiary is responsible for the 
remaining 20 percent (called the coinsurance or cost-sharing). There-
fore, the higher the total payment amount, the higher the beneficiary 
coinsurance amount. Depending on the beneficiary’s situation, the 
coinsurance may be paid by the Medicaid program, a supplemental 
insurance plan, or by the beneficiary themselves. Almost 90 percent 
of beneficiaries have some form of supplemental coverage to help 
meet their cost-sharing requirements.28 Under Part B, the beneficiary 
continues to be responsible for 20 percent of the cost of their drugs 
no matter how much they have already spent on drugs; there is no 
protection against catastrophic costs as exists under Part D. 
Decisions about the specific drug that is provided and the setting 
in which that drug is administered can have significant effect on 
the amount the beneficiary will pay out of pocket for the drug. The 
disparate payment rates shown in Table 3 result in equally dispa-
rate beneficiary cost-sharing. For example, a beneficiary receiving 
cladribine for treatment of hairy cell leukemia would be responsible 
for $5.85 for every unit administered in a physician office, $5.74 for 
every unit administered in a hospital outpatient department, and 
$12.34 for every unit administered through a DME infusion pump.
Understanding the effect of drug administration choices on benefi-
ciary cost-sharing is further complicated when Part D is taken into 
consideration. In some instances, physicians and beneficiaries may 
have a choice between multiple treatment options, some of which are 
covered under Part B and others under Part D. Appendix B describes 
key elements of Part D cost-sharing. As a percentage, coinsurance 
under Part B tends to be lower than under Part D (20 percent com-
pared with 25 percent). However, each Part D plan negotiates its own 
prices for covered drugs, and that price may be lower than the price 
for the Part B alternative.29 Therefore, even though the coinsurance 
percentage tends to be higher under Part D, the amount the benefi-
ciary has to pay out of pocket may be lower for a treatment option 
under Part D if the beneficiary is enrolled in a plan with a negotiated 
price below the payment rate for the Part B option. In addition, Part 
D cost-sharing for the same drug can increase or decrease over the 
course of the year depending on the beneficiary’s total drug costs 
August 31, 2009 NAtioNAl HeAltH Policy Forum 
16
under Part D. See Appendix B for an example illustrating the finan-
cial impact of choosing a treatment option under Part B or Part D.
assessing ParT B drug PayMenT PoLicy
The Medicare Modernization Act of 2003 (MMA) changed the basis 
of payment for Part B drugs to better align Medicare payment with 
the actual prices paid. Prior to 2005, Medicare payment generally ex-
ceeded costs, in some instances by more than 600 percent.30 Prior to 
the passage of the MMA, spending on drugs administered in physi-
cian offices was increasing at 25 percent per year. With the implemen-
tation of MMA payment changes in 2005, actual spending dropped 
almost 8 percentage points. Since then, Medicare spending on Part B 
drugs has started to increase again, although at a less rapid pace.31 
With the transition to ASP, physicians and suppliers raised concerns 
that Medicare beneficiaries would no longer have access to all drugs, 
or that beneficiaries in certain parts of the country, such as rural 
areas, would have to travel farther to receive Part B drugs. Congress 
mandated that Medicare pay 6 percent more than ASP with the ex-
pectation that most physicians and suppliers would be able to pur-
chase drugs below that rate. Studies of the transition suggest that 
this expectation is being met. MedPAC assessed the impact of pay-
ment changes for oncology services and found that neither access 
nor quality of care was affected. Both small and large practices were 
able to purchase drugs for less than the Medicare payment rate.32 
GAO similarly found that oncology practices were generally able to 
purchase the most-used chemotherapy drugs at or below ASP.33
Some observers note that the transition to ASP revises the calculation 
of the payment amount but does not fundamentally change the way 
Medicare pays for Part B drugs, nor does it remove the incentives 
to “game” the system. The Medicare payment rate still exceeds the 
sales price of most drugs. Further, because the difference between 
cost and the payment rate is smaller under the ASP methodology 
than under AWP, the incentive to maximize profits by providing 
greater quantities of drugs may have increased.34 
If Medicare payment rates are not so low as to negatively affect bene-
ficiary access to those drugs, are they too high? Some observers point 
to rates paid by other government agencies such as the Department 
of Veterans Affairs, Department of Defense, or the Indian Health 
www.nhpf.org
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Service, which are typically below the Medicare amount, and con-
clude that Medicare is paying too much. They recommend setting 
the Medicare payment at the price paid by these other programs. 
Critics call such an approach shortsighted because of the size of the 
Medicare program and the number of sales that would then occur 
at the lower rates if those prices were adopted. They predict that 
any Medicare savings would be temporary because manufacturers 
would increase their price to all entities to avoid the mandated prices 
to the enormous Medicare population. Expenditures under the other 
programs, they argue, would also increase.35
concLusion
Changes under the MMA appear to have addressed concerns about 
significant overpayments by Medicare for Part B drugs. However 
Part B drugs continue to account for a sizeable portion of total Part 
B spending. The extent to which Part B drugs are included in re-
forms, such as bundled payments, intended to better align payment 
incentives to avoid overutilization of services is a tough policy deci-
sion. Such decisions must be made recognizing both the complicated 
framework of Part B coverage and payment and its complex interac-
tion with Part D coverage.
endnoTes
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Price listed in certain compendia 









Average price paid to the manufac-
turer for the drug in the United States 
by wholesalers for drugs distributed 
to the retail pharmacy class of trade 
Medicaid Includes discounts other 




Average price for sales to all pur-
chasers excluding sales that are ex-
empt from the Medicaid best price 
calculation 
Medicare Includes volume discounts, 
prompt pay discounts, cash 
discounts, free goods that 
are contingent on any pur-
chase requirement, charge-
backs, and rebates
—— Best Price Lowest price available to any whole-
saler, retailer, provider, HMO, non-
profit entity or government entity 
excluding sales to: IHS, VA, DOD, 
or certain Public Health Service 
programs; Federal Supply Sched-
ule; state pharmaceutical assistance 
programs; Part D plans or qualified 
retiree drug subsidy plans
Medicaid Includes cash discounts, free 
goods that are contingent 
on any purchase require-





The manufacturer’s list price for 









Price that a prudent physician or 
supplier would pay for the drug 
or biological as determined by the 
HHS Inspector General
Medicare Includes discounts, rebates, 
and other price concessions 
routinely made available 
to prudent physicians or 
suppliers
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Part D Beneficiary a Beneficiary B
Drug costs $ 1,200 $ 6,000
Cost-sharing $ 595 $ 4,196
For some conditions, like rheumatoid arthritis or some forms of cancer, 
available drug treatments include options that are covered under Part 
B and others that are covered under Part D. Even if only financial (not 
clinical) considerations are taken into account, determining whether a 
Part B drug or a Part D drug is right for a beneficiary is complicated.
aPPENDix B
Weighing the options
is Part B or Part D 
Better for the Beneficiary?
Consider the following scenario...
Beneficiary a and Beneficiary B are enrolled in Part 
D plans. Both have annual Part D drug costs and out-of-
pocket cost-sharing (deductible and coinsurance).
Suppose both beneficiaries are diagnosed with a new condition for which there are two treatment 
options. The first option is a Part B drug (Drug X) that costs $1,000 a month. The second option is a Part D 
drug (Drug Y) that costs $500 a month.
This table shows the impact on 
the out-of-pocket costs for each 
beneficiary of choosing either 
Drug X or Drug Y.
As this example shows, the bot-
tom line can be surprising. For 
Beneficiary A, who has relatively 
low drug costs, choosing Drug 
X that costs twice as much as 
Drug Y actually results in lower 
out-of-pocket costs. This happens because, typically under Part D, the coinsurance percentage changes as 
the beneficiary’s drug costs increase. The percentage starts at 25 percent for the initial cost-sharing period, 
increases to 100 percent after that, and then drops to 5 percent when the beneficiary qualifies for catastrophic 
coverage. In contrast, Part B coinsurance is constant at 20 percent.
Using Drug Y would increase Beneficiary A’s Part D drug costs significantly, but not enough to qualify for 
catastrophic coverage. Beneficiary B already had relatively high Part D drug costs. For him, choosing Drug 
Y would result in lower out-of-pocket costs because the additional Part D drug costs would qualify him for 
catastrophic coverage. There is no catastrophic coverage for Part B drugs.
out-of-Pocket Costs
Beneficiary a Beneficiary B
Drug x Drug y Drug x Drug y
ParT B
Drug costs $ 12,000 $ 0 $ 12,000 $ 0
Cost-sharing $ 2,400 $ 0 $ 2,400 $ 0
ParT d
Drug costs $ 1,200 $ 7,200 $ 6,000 $ 12,000
Cost-sharing $ 595 $ 4,402 $ 4,196 $ 4,642
Total Drug Cost-sharing $ 2,995 $ 4,402 $ 6,596 $ 4,642
